Rigel Pharmaceuticals, Inc. (RIGL)

Check out top investors' recommendation for RIGL
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
N/A
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for the treatment of rheumatoid arthritis; R343, an inhaled SYK inhibitor that is in Phase II clinical trials to treat asthma; R333, a topical dermatological janus kinase (JAK)/SYK inhibitor, which is in Phase II clinical trials for the treatment of discoid lupus erythematosus; and R348, a topical ophthalmic JAK/SYK inhibitor that is in Phase I clinical trials to treat keratoconjunctivitis sicca. The company also conducts preclinical studies for an oral activator of adenosine monophosphate activated protein kinase to enhance the body's energy utilization and restore muscle endurance in chronically ill subjects. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB to develop and commercialize oral SYK inhibitors; and Daiichi Sankyo to conduct research related to drug targets called ligases that control cancer cell proliferation through protein degradation, as well as a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 11, '19     7.50  Jan 11, '20  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 05, '18     7.50  Oct 05, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Aug 09, '18     7.50  Aug 09, '19  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Aug 08, '18     8.00  Aug 08, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jun 26, '18     7.50  Jun 26, '19  N/A 
Eun Yang Jefferies & Co. Buy   Apr 04, '18     5.00  Apr 04, '19  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Apr 03, '18       Apr 03, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Mar 07, '18     7.00  Mar 07, '19  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 19, '18     7.00  Jan 19, '19  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Dec 21, '17     6.00  Dec 21, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Dec 11, '17     7.00  Dec 11, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Nov 06, '17     7.00  Nov 06, '18  N/A 
David Steinberg Deutsche Bank Securities Buy   Oct 05, '17     5.00  Oct 05, '18  N/A 
Eun Yang Jefferies & Co. Buy   Oct 03, '17     5.00  Oct 03, '18  N/A 
Michael Yee RBC Capital Markets Buy   Sep 04, '17     5.00  Sep 04, '18  N/A 
Jim Birchenough BMO Capital Markets Buy   Mar 08, '17     4.00  Mar 08, '18  N/A 
Jim Birchenough BMO Capital Markets Buy   Jan 30, '17     4.00  Jan 30, '18  N/A 
Eun Yang Jefferies & Co. Buy   Nov 02, '16     5.00  Nov 02, '17  N/A 
Joshua Schimmer Lazard Capital Markets Buy   Nov 02, '16     11.00  Nov 02, '17  N/A 
M Ian Somaiya Piper Jaffray Buy   Aug 17, '16       Aug 17, '17  N/A 
< previous12